Search results for "castration resistant prostate cancer"
showing 4 items of 4 documents
Development of polypeptide-based therapeutics for the treatment of castration resistant prostate cancer
2019
El cáncer de próstata (CaP) es el segundo cáncer más frecuente en los hombres. Los estudios han establecido el gen de fusión (T2E) compuesto por TMPRSS2 (serina proteasa dependiente de andrógenos) y ERG (factor de transcripción de la familia ETS) como un biomarcador potencial de CaP. La progresión en el CaP incluye tanto el receptor de andrógenos (AR) como el receptor del factor de crecimiento de insulina 1 (IGF-1R), y el tratamiento con un anticuerpo anti-IGF-1R (AVE1642) ha demostrado un gran potencial en el tratamiento de los pacientes con CaP T2E-positivos. Por ello, el desarrollo de terapias personalizadas basadas en polímeros terapéuticos puede favorecer el tratamiento de CaP para un …
Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide
2022
Introduction: This monocentric, single-arm, retrospective study investigated the role of stereotactic body radiotherapy in patients with metastatic castration resistant prostate cancer who experienced oligoprogression during androgen receptor targeted agents. Methods: We retrospectively enrolled metastatic castration resistant prostate cancer patients treated with androgen receptor targeted agents between December 2016 and January 2022. All patients experienced an oligoprogression (defined as the appearance and/or the progression of ⩽5 bone or nodal or soft tissue metastases) during treatment with androgen receptor targeted agents and received stereotactic body radiotherapy upon oligoprogre…
Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors
2019
[EN] The development and advancement of prostate cancer (PCa) into stage 4, where it metastasize, is a major problem mostly in elder males. The growth of PCa cells is stirred up by androgens and androgen receptor (AR). Therefore, therapeutic strategies such as blocking androgens synthesis and inhibiting AR binding have been explored in recent years. However, recently approved drugs (or in clinical phase) failed in improving the expected survival rates for this metastatic-castration resistant prostate cancer (mCRPC) patients. The selective CYP17A1 inhibition of 17,20-lyase route has emerged as a novel strategy. Such inhibition blocks the production of androgens everywhere they are found in t…
Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?
2019
Introduction: Radium-223 (223Ra) improves symptoms and survival in patients with bone metastatic castration-resistant prostate cancer (mCRPC). Study aim: To evaluate the impact of a previous radical prostatectomy (RP) on the outcome of 223Ra therapy in mCRPC patients. The primary prostate tumor left untreated could progress during 223Ra treatment. Materials and methods: mCRPC symptomatic patients treated with 223Ra were enrolled. Luteinizing Hormone-Releasing Hormone analogue was maintained. No other anticancer therapy was given. 223Ra was administered i.v. at the dose of 55 kBq/kg every 4 weeks for 6 cycles. Patients were stratified according to previous RP or not. Hematological toxicity w…